Viveve Medical (VIVE) Receives “Buy” Rating from Mizuho

Mizuho reiterated their buy rating on shares of Viveve Medical (NASDAQ:VIVE) in a research note published on Friday. They currently have a $10.00 price target on the stock.

Other analysts have also issued reports about the company. Northland Securities assumed coverage on Viveve Medical in a research note on Friday. They set an outperform rating and a $8.00 price objective on the stock. Cowen set a $11.00 price objective on Viveve Medical and gave the company a buy rating in a research note on Monday, October 23rd. Finally, ValuEngine lowered Viveve Medical from a sell rating to a strong sell rating in a research note on Sunday, December 31st. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Viveve Medical has a consensus rating of Buy and a consensus price target of $10.00.

Shares of Viveve Medical (NASDAQ:VIVE) opened at $5.01 on Friday. The company has a debt-to-equity ratio of 2.72, a quick ratio of 3.63 and a current ratio of 3.89. Viveve Medical has a one year low of $3.75 and a one year high of $11.16. The stock has a market capitalization of $97.33, a price-to-earnings ratio of -2.33 and a beta of -0.67.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The company had revenue of $4.07 million for the quarter, compared to the consensus estimate of $4.10 million. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. The business’s revenue for the quarter was up 120.1% compared to the same quarter last year. research analysts anticipate that Viveve Medical will post -2.04 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers purchased a new position in Viveve Medical during the second quarter worth about $110,000. JPMorgan Chase & Co. purchased a new position in Viveve Medical during the second quarter worth about $151,000. Virtu KCG Holdings LLC purchased a new position in Viveve Medical during the second quarter worth about $169,000. Granahan Investment Management Inc. MA grew its position in Viveve Medical by 32.6% during the third quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock worth $535,000 after buying an additional 25,097 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new position in Viveve Medical during the second quarter worth about $189,000. Institutional investors and hedge funds own 66.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/09/viveve-medical-vive-receives-buy-rating-from-mizuho.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply